A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study
The FIL_RECANZ (ClinicalTrials.gov: NCT02371161) is a prospective study evaluating salvage with autologous stem cell transplantation (ASCT) in aggressive B-cell lymphoma patients aged 65 - 75, fit according to the FIL Geriatric Assessment (CGA). Seventy patients were analyzed who received salvage with three cycles of a platinum-based regimen. Response to salvage was 44% (21 complete, 10 partial remissions). Twenty-seven responding subjects underwent ASCT following BEAM/FEAM conditioning with a median of 5.6 × 10<sup>6</sup> CD34+ cells/kg reinfused: 24 (89%) obtained complete remission, in 22 lasting > 12 months. After a median of 28 months from ASCT, 2-year event-free survival was 54%, with the most common grade 3-4 non-hematological toxicity consisting of gastrointestinal (10%) and infectious (8%). No treatment-related mortality was recorded within 100 days following ASCT. Our data indicate that CGA enables fit older patients to undergo ASCT with favorable tolerance and efficacy. These results may serve as a benchmark to assess more effective pre-ASCT therapies.
Authors
- Mauro Turrini (ORCID: https://orcid.org/0000-0001-5299-8456)
- Raffaella Marcheselli (ORCID: https://orcid.org/0000-0002-9506-2268)
- Francesco Rotondo (ORCID: https://orcid.org/0000-0001-8599-7994)
- Monica Tani (ORCID: https://orcid.org/0000-0002-5016-2054)
- Luca Castagna (ORCID: https://orcid.org/0000-0002-6239-7387)
- Donato Mannina (ORCID: https://orcid.org/0000-0001-8665-1258)
- Guido Gini (ORCID: https://orcid.org/0000-0002-1368-6342)
- Vittorio Ruggero Zilioli (ORCID: https://orcid.org/0000-0001-6915-2246)
- Alessandro Re (ORCID: https://orcid.org/0000-0003-1156-6395)
- Francesca Re (ORCID: https://orcid.org/0000-0003-1374-567X)
- Mariagrazia Michieli (ORCID: https://orcid.org/0000-0001-6302-0488)
- Chiara Pagani (ORCID: https://orcid.org/0000-0002-6962-4466)
- Michele Clerico
- Francesco Merli (ORCID: https://orcid.org/0000-0002-0979-7883)
- Maria Christina Cox (ORCID: https://orcid.org/0000-0002-8597-8459)
- Luigi Marcheselli
- Francesco Malaspina (ORCID: https://orcid.org/0000-0003-3041-9606)
- Alessandra Tucci (ORCID: https://orcid.org/0000-0003-3052-7463)
- Gerardo Musuraca (ORCID: https://orcid.org/0000-0003-1947-1032)
- Annalisa Arcari (ORCID: https://orcid.org/0000-0001-5337-5947)
- Giuseppe Rossi (ORCID: https://orcid.org/0000-0001-8377-2898)
- Federica Cavallo (ORCID: https://orcid.org/0000-0003-2047-1099)
- Manuela Zanni
Institutions
- Marche Polytechnic University (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- ASL Roma (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale Santa Maria (IT)
- Azienda Socio Sanitaria Territoriale Lariana (IT)
- Fondazione Intergruppo Italiano Linfomi Onlus (IT)
- Centro di Riferimento Oncologico (IT)
- Ospedale di Parma (IT)
- Guglielmo da Saliceto Hospital (IT)
- Policlinico Tor Vergata (IT)
- Ospedale degli Infermi (IT)
- Fondazione Humanitas per la Ricerca (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- Ospedale Valduce (IT)
- Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT)
- University of Turin (IT)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2025-03-08
- DOI
- https://doi.org/10.1080/10428194.2025.2471499
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00